| F |
| Fabbrini N. J. |
- |
Effectiveness of polybrene neutralization of heparin and low-molecular weight heparin in plasma |
| Faber J. |
- |
Variation in plasminogen activator inhibitor-1 gene and risk of meningococcal disease |
| Faber W. R. |
- |
Post-thrombotic complaints are not related to factor V Leiden mutation or elastic compression stockings: results of the MEGA Study |
| Fabre M. |
- |
Fatal intra cerebral hemorrhage due to severe vitamin K deficiency disclosing cystic fibrosis |
| Fabri D. R. |
- |
Alternative second-line treatment for chronic immune thrombocytopenic purpura with sulphasalazine |
| Fabris F. |
- |
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study |
| Facchinetti F. |
- |
Elevated plasma levels of factor VIII in women with early recurrent miscarriage |
| |
- |
Reduced platelet sensitivity to nitric oxide donors in patients with a history of preeclampsia |
| Faccini G. |
- |
Low vitamin B6, markers of inflammation, and coronary artery disease |
| Fadin M. |
- |
Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III |
| |
- |
Incidence of recurrent ischemic stroke in children with coagulation abnormalities |
| |
- |
The incidence of venous thromboembolism in carriers of single identified prothrombin G20210A: a retrospective cohort study |
| |
- |
The incidence of venous thromboembolism in homozygous or double heterozygous carriers of the factor V Leiden mutation, prothrombin 20210 A mutation and HR2 aplotype: interim report |
| |
- |
Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft |
| Fahs S. A. |
- |
The sorting signal for von Willebrand factor (vWF) granular storage lies within the first 140 amino acids of the D2 domain of the VWF propeptide (VWFpp) |
| Fahs S. A. |
- |
Cloning and expression of full-length recombinant porcine von Willebrand factor |
| Fahs S. A. |
- |
Comparative response of plasma VWF in normal and von Willebrand disease dogs to up-regulation of VWF mRNA by Interleukin-11 vs. Weibel–Palade body release by Desmopressin (DDAVP) |
| Faioni E. M. |
- |
Intruterine Growth Restriction (IUGR) and thrombophilic polymorphisms |
| |
- |
The Factor V HR2 haplotype and the risk of venous thrombosis: a metanalysis |
| |
- |
Does plasma homocysteine influence the in vitro anti-coagulant response to activated Protein C? |
| |
- |
Genetically defined protein S (PS) deficiency is associated with venous thrombosis |
| Faioni E. M. |
- |
Contribution of factor V deficiency to the thrombotic risk associated with factor V HR2 |
| Faioni (for Prosit) E. M. |
- |
PROSIT: functional analysis of identified PROS1gene mutations |
| Fairlie F. M. |
- |
Comparison of cytotrophoblast gene expressed in normal and pre-eclamptic placenta |
| Falanga A. |
- |
Low-molecular weight heparin (LMWH) enoxaparin counteracts the expression of endothelial cell tissue factor elicited by malignant cells |
| |
- |
The synthetic retinoic acid receptor (RAR)-gamma agonist CD437 reduces procoagulant activity and induces apoptosis in breast cancer cells |
| |
- |
Low-molecular weight heparins (LMWH) modulate the functional adhesion of tumor cells to the vascular endothelium |
| Falanga A. |
- |
Role of polymorphonuclear (PMN) leukocyte activation in the formation of PMN-platelet aggregates in Essential Thrombocythemia (ET) and Polycythemia Vera (PV) |
| Falanga A. |
- |
Effect of the LMWHs dalteparin and enoxaparin on tissue factor and thrombomodulin expression by endothelial cells |
| Falantes J. |
- |
Natural history of hepatitis C infection in hemophilia patients at Hospital Universitario Virgen del Rocío (Sevilla, Spain) |
| |
- |
Interferon and ribavirin in patients with chronic hepatitis C and congenital bleeding disorders |
| Falaschi F. |
- |
Objective assessment of deep vein thrombosis and pulmonary embolism can be deferred without increased risk of thrombosis: a practical approach based on the pretest clinical model, d-dimer and the use of low molecular weight heparins |
| Falati S. |
- |
Opposing effects of P-selectin and PECAM-1 on arterial thrombus growth and stability in vivo |
| Falciani M. |
- |
Effects of HRT with estradiolvalerate 2-mg + levonorgestrel 75 µg (NUVELLE®) on clotting and lipid profile |
| Falciani M. |
- |
Evaluation of the fibrinolytic capacity before and after venous occlusion performed by serum d-dimer test after standardized coagulation |
| Falcinelli E. |
- |
LPS induced MMPs release in mice: role of platelets and inhibition by NCX4016 (nitroaspirin) |
| Falcinelli E. |
- |
Chlamydia pneumoniae seropositivity is associated with increased inflammatory characteristics in atherosclerotic plaques |
| |
- |
Platelet-derived nitric oxide (NO) is suppressed by hyperhomocysteinemia: a possible prothrombotic effect |
| Falcó C. |
- |
Quantitative real-time gene expression analysis for several components of fibrinolytic and matrix metalloproteinase systems in primary breast cancer |
| Falco A. |
- |
Preconceptional and gestational enoxaparin regimes adjusted to fertility program to prevent preclinical, embryonic and fetal loss in women with Recurrent Pregnancy Loss (RPL) and thrombophilia |
| Falcó C. |
- |
Lipoprotein (a) levels and isoforms and fibrinolytic parameters in young survivors of myocardial infarction with and without peripheral artery disease |
| |
- |
Quantitative real-time reverse transcription-PCR (RT-PCR) assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1 and tissue metalloproteinase inhibitor type 1 gene expression and protein levels in endometriosis |
| Fan H. C. |
- |
A G-to-A mutation at -33 position in the promoter region of thrombomodulin gene and non-O blood group are associated with idiopathic venous thromboembolism: Taiwan Thrombophilia Study |
| Fantchenko N. D. |
- |
Hemostasis during first trimester of spontaneous pregnancy and pregnancy after IVF&ET |
| |
- |
Haemostasis parameters and different forms of Ovarian Hyperstimulation Syndrome |
| Fante F. |
- |
Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft |
| Fantuzzi J. |
- |
Antithrombotic effects of selective P2Y1 and P2Y12 antagonists in anesthetized rats |
| Faraci F. M. |
- |
Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice |
| Fareed J. |
- |
Malignancy-related thrombotic state is independent of defects in Factor V Leiden, prothrombin 20210 and MTHFR. Results from the initial profiling of cancer patients entering in a secondary prevention of venous thrombosis with enoxaparin (ONCENOX) |
| Fareed J. |
- |
Inhibition of procarboxypeptidase U by tinzaparin. A potential mechanism of its profibrinolytic actions |
| Fareed D. |
- |
Activated clotting time guided dosage optimization of a low molecular weight heparin (tinzaparin) for surgical and interventional indications |
| |
- |
Oral antithrombin agents comprise the regulatory functions of thrombin |
| Fareed J. |
- |
New insights into the pharmacology of Argatroban and potential clinical relevance |
| Fareed D. |
- |
Molecular-weight dependence on the inhibition of procarboxypeptidase U by heparin and a polydeoxyribonucleotide derived antithrombotic agent (Defibrotide) |
| Fareed J. |
- |
Molecular-weight dependence on the inhibition of procarboxypeptidase U by heparin and a polydeoxyribonucleotide derived antithrombotic agent (Defibrotide) |
| |
- |
Prevention of venous thromboembolism in orthopedic trauma patients receiving heparin thromboprophylaxis – a substudy analysis of autopsy-confirmed fatal pulmonary embolism |
| |
- |
Heparin-induced anti-platelet antibodies in very low birth-weight infants |
| Fareed J. |
- |
Argatroban anticoagulation inhibits thrombin generation and its rebound during percutaneous interventional procedures |
| Fareed J. |
- |
Lack dose-response with Fondaparinux and Idraparinux is due to endogenous antithrombin saturation |
| Fareed J. |
- |
Prevalence of anti-Erythropoietin antibodies in end stage renal disease patients treated with recombinant Erythropoietin |
| Fareed J. |
- |
Pharmacodynamics and pharmacokinetics of anti-Xa potency adjusted heparin derived oligosaccharides in nonhuman primates: implications in dosage optimization |
| Fareed J. |
- |
Polypharmacologic actions of low-molecular-weight heparins: lessons from clinical trials |
| Fareed J. |
- |
The irrelevance of International Normalized Ratio in the monitoring of anti-IIa and anti-Xa drugs |
| |
- |
Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications |
| |
- |
Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins |
| |
- |
Interaction of thrombolytic agents with argatroban: pharmacological implications |
| |
- |
Non-coagulant variants of thrombin are capable of activating procarboxypeptidase U |
| |
- |
Heparin derived oligosaccharides are capable of passing through the blood brain barrier: experimental evidence in a rat model |
| Fareed D. |
- |
Nitric oxide levels are up-regulated in patients with malignancy associated hypercoagulable state |
| Fareed J. |
- |
Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis |
| |
- |
Serine proteases–mediated serotonin release and its inhibition by argatroban and other direct thrombin inhibitors: Implications in the control of thrombogenesis |
| Fareed D. |
- |
Heparinase I digestion of tinzaparin: a novel approach to neutralize the anti-coagulant and potential hemorrhagic effects of low molecular weight heparin |
| Fareed J. |
- |
Fibrinopeptide-A generation inhibition by anti-Xa drugs and its correlation with activated clotting time |
| |
- |
Elevated soluble thrombomodulin levels in patients with acute coronary syndrome: down-regulation by anticoagulant dosage of low molecular weight heparins |
| |
- |
Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications |
| Fareed D. |
- |
Species dependence on nitric oxide generation: pharmacological implications on animal modeling |
| Farías C. E. |
- |
Control of von Willebrand factor multimer size by a fibronectin related substance |
| |
- |
Influence of factor VIII (fVIII) levels in patients treated with DDAVP on the activated protein C resistance (APCR) |
| Farías C. |
- |
Von Willebrand factor cleaving protease (VWFCP) activity in patients with pre-eclampsia history: preliminary results |
| |
- |
Virtual decrease of von Willebrand Factor-cleaving protease (ADAMTS13) after infusion of desmopressin (DDAVP) |
| Farías C. E. |
- |
Comparative study of conformation sensitive gel electrophoresis and DNA sequencing for polymorphisms and mutation detection in von Willebrand disease type 2 N |
| Fariciotti A. |
- |
Recombinant activated Factor VII (rFVIIa) for the treatment of bleeding secondary to acquired factor VIII inhibitor |
| Farjadian S. |
- |
Identification of factor IX mutations in 17 Iranian families with hemophilia B |
| Farndale R. W. |
- |
Functional significance of single-nucleotide polymorphisms in the glycoprotein VI gene |
| |
- |
The low frequency allele of glycoprotein VI raises the threshold for platelet activation by collagen and collagen-related peptides |
| |
- |
Difference in binding of human and murine glycoprotein VI to collagen-related peptide and fibrillar collagen |
| |
- |
Role of PI 3-kinase in glycoprotein VI-dependent calcium signaling in human platelets |
| |
- |
Cross-talk between alpha2beta1 integrin and GPVI receptors regulates actin polymerization through Rho GTPase and MAP kinase Erk1/2 signaling pathways in human megakaryocytes |
| Farndale R. |
- |
The use of synthetic triple helical peptides to define a recognition motif in collagen III for human platelet receptor, Glycoprotein VI |
| Farndale R. W. |
- |
Human glycoprotein VI: identification and blockade of the collagen-binding surface |
| |
- |
Regulation of GPVI-mediated platelet procoagulant response and degranulation |
| |
- |
Platelet glycoprotein VI has evolutionary conserved immunoglobulin domains, but a highly polymorphic stem and cytoplasmic domain |
| |
- |
Interplay of glycoprotein Iba, integrin a2b1 and glycoprotein VI is required for human thrombus formation under flow |
| Farr M. |
- |
Influence of platelet glycoprotein IIIa PlA polymorphism on mean platelet volume and vWF after coronary stent implantation |
| |
- |
The G allele of IL-6–174G/C polymorphism is a risk factor for restenosis after coronary stent implantation by increased inflammation and platelet activation |
| Farrell D. H. |
- |
Inhibition of retinal neovascularization in mice by antisense phosphorodiamidate morpholino oligomer against av integrins |
| |
- |
Inhibition of coagulation and thrombin-mediated platelet aggregation by plasmin-cleaved fibrinogen g'-chain carboxyl terminal peptide |
| Fatini C. |
- |
New risk factors for coronary artery disease: the endothelial nitric oxide synthase polymorphisms |
| |
- |
Angiotensin converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation |
| |
- |
TAFI plasma levels are not increased in ischemic heart disease patients admitted to a coronary care unit |
| Fauchere J. L. |
- |
Specific phosphatidylserine exposure and microparticules shedding induced by a synthetic peptide |
| Fauchère J. L. |
- |
Influence of selective nonpeptide PAR-1 and PAR-4 antagonists on thrombin-induced aggregation of human platelets |
| Faure S. |
- |
Fractalkine/CX3CL1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses |
| Faure V. |
- |
The uremic retention solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair in vitro |
| Fauvel-Lafeve F. |
- |
Primordial role of the P2Y12 ADP receptor in different phases of platelet–collagen interactions |
| |
- |
Platelet aggregates modulate the adhesion of breast adenocarcinoma cells (MDA-MB-231) to endothelial cells and their matrix in whole blood and under flow conditions |
| Favaloro E. J. |
- |
Laboratory diagnosis of congenital thrombophilia: current and past practice in Australia |
| |
- |
Laboratory diagnosis of von Willebrand Disorder: current and past practice in Australasia |
| |
- |
Laboratory assessment of acquired thrombophilia: current and past experience in Australasia with lupus anticoagulant (LA) and anti-cardiolipin antibody (ACA) testing |
| Faverdin C. |
- |
Evidence for extracellular signal-regulated kinase 1/2 activation by thrombin that is independent on epidermal growth factor receptor transactivation in vascular smooth muscle cells |
| Favier R. |
- |
Normal values of total and free TFPI levels in the newborn and in children |
| |
- |
Comparison of inherited and acquired thrombophilia in cerebral venous thrombosis and pulmonary embolism or deep vein thrombosis of the leg |
| |
- |
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lanka ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X |
| Favretto G. |
- |
Management of oral anticoagulant therapy in the perioperative period: preliminary results of the application of an operative protocol |
| Fay P. |
- |
Characterization of a monoclonal antibody to factor VIII: epitope mapping and mechanism of inhibition |
| Fay P. J. |
- |
Copper binding site(s) in factor VIII involved in the regulation of cofactor specific activity |
| Fay P. J. |
- |
Evidence that interaction of the A2 domain of factor VIIIa with factor IXa occurs over an extended surface |
| Fazzio M. |
- |
Elevated plasma levels of factor VIII in women with early recurrent miscarriage |
| |
- |
Reduced platelet sensitivity to nitric oxide donors in patients with a history of preeclampsia |
| Feder J. |
- |
Studies of blood coagulation and platelet function in thoracic surgery utilizing a point of care instrument, a free oscillation rheometer |
| Federici A. B. |
- |
An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio |
| |
- |
Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study |
| |
- |
In vitro expression of 4 novel mutations identified in type 1 von Willebrand disease patients |
| |
- |
Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease |
| |
- |
In vitro expression study of two naturally occurring mutations (D141Y and C275S) of the von Willebrand factor (VWF) proeptide that result in defective multimerization and secretion |
| |
- |
Platelet integrin a2 SNP 807C is a predictor of bleeding in Von Willebrand Disease (VWD) type 1 |
| |
- |
Evaluation of a new quantitative, rapid test (VWF-LIA) for the diagnosis of type 1 VWD |
| |
- |
New automated von Willebrand factor activity assay to distinguish type 1 and type 2 von Willebrand disease (VWD) |
| |
- |
Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study |
| Federici A. |
- |
Management of VWD with VWF/FVll concentrates: Results from current studies and surveys |
| Federici A. B. |
- |
Expression of a new candidate mutation, G1629R, identified in an Italian patient with type 2A von Willebrand disease |
| |
- |
Sensitivity and specificity of PFA-100® vs. bleeding time in the diagnosis of type 1 von Willebrand disease (VWD) |
| Federici A. |
- |
Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration |
| Federico A. |
- |
Coagulation and complement inhibitors levels predict outcome in patients with severe sepsis |
| Fedi S. |
- |
High plasma homocysteine concentrations in cerebrovascular patients with Fabry disease |
| |
- |
Protein Z levels in acute coronary syndromes |
| |
- |
Emerging prognostic factors in ischemic heart disease |
| Fedi S. |
- |
Homocysteine plasma levels in primary biliary cirrhosis (PBC) |
| Fedi S. |
- |
Effects of HRT with estradiolvalerate 2-mg + levonorgestrel 75 µg (NUVELLE®) on clotting and lipid profile |
| |
- |
Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients |
| Fedortseva R. F. |
- |
Unusual persistent cell damages in irradiated rat endothelium as a model in study pathophysiology of atherosclerosis and thrombosis |
| Fedotova I. |
- |
The influence of cyclooxygenase-2-selective nonsteroid anti-inflammatory drugs on bleeding complications in aspirin users |
| |
- |
Effect of etanercept on procoagulant activity and fibrinolysis in patients with rheumatoid arthritis |
| Feige M. |
- |
Binding of minute amounts of thrombin to GPIbalpha accelerates early platelet reactions, but not the platelet procoagulant response |
| Feijge M. |
- |
Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype |
| Feijge M. A. H. |
- |
Glycoprotein Ib and integrin a IIbb 3 contribute to GPVI-dependent vWF-collagen induced thrombus formation under flow |
| |
- |
Function of calcium-dependent protein kinase C in platelet aggregation and thrombus formation: Studies using a chemically synthesized TAT-linked peptide blocking the C2 domain of protein kinase C-beta |
| |
- |
Effects of dietary fish oil on coagulation and platelets |
| |
- |
Effects of platelet agonists and antiplatelet agents on thrombin formation in human plasma |
| |
- |
Storage of apheresis platelets leads to reduced adhesiveness and thrombogenic activity in flowing whole blood ex vivo |
| Feijoo R. |
- |
Acquired platelet dysfunction with eosinophilia in children: A tropical disease present in Venezuela |
| |
- |
Factor XI deficiency in Mestizo Venezuelan population |
| Feistritzer C. |
- |
Eosinophils as a novel target for protein C |
| Feistritzer C. |
- |
Expression of endothelial protein C receptor by human neutrophils and its role in cell migration |
| Felaco M. |
- |
Inhibition of 3-Hydroxy-3-methylglutaryl coenzyme-A reductase attenuates expression of inducible nitric oxide synthase in cardiac myoblasts – Possible link to direct myocardial protection during ischemia-reperfusion |
| Feldman B. |
- |
Final results from the Canadian hemophilia dose escalation prophylaxis trial |
| Feldman P. A. |
- |
Purification and formulation of a dual viral-inactivated fibrinogen concentrate for use in a fibrin sealant |
| Felices R. |
- |
Heritability of plasma antiphospholipid antibodies |
| |
- |
The 46C®T polymorphism in the F12 gene is a risk factor for ischemic stroke |
| Felíu Torres A. |
- |
Biological and clinical DDAVP response in children with von Willebrand disease (VWD) |
| Feliu Torres A. |
- |
Arterial ischemic stroke (AIS) in children: a prospective 10-year registry in Argentina |
| |
- |
Venous thromboembolism (VTE) in children: A prospective 10-year registry in Argentina |
| |
- |
Cerebral sinovenous thrombosis (SVT) in children: a prospective 10-year registry in Argentina |
| Feliziani V. |
- |
Are daily doses of 80 and 160 mg of aspirin bioequivalent? A pharmacokinetic and pharmacodynamic approach |
| Feng Y. |
- |
Clinical thrombolytic trial of a new type of tissue-plasminogen activator in patients with acute stroke |
| Fenger-Eriksen C. |
- |
Real-time whole-blood coagulation following ex vivo hemodilution with plasma substitutes: reversal of the coagulopathy by a fibrinogen concentrate |
| Fennema H. |
- |
Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers |
| Fenske C. |
- |
Enhanced thrombus recanalization and resolution after vascular endothelial growth factor (VEGF) naked DNA gene transfer |
| Fenton J. |
- |
PAR-1 (1–41) and SFLLRN independently propagate platelet activation |
| Fenton J. W. |
- |
Serine proteases–mediated serotonin release and its inhibition by argatroban and other direct thrombin inhibitors: Implications in the control of thrombogenesis |
| Fenton II J. W. |
- |
Statin regulation of extrinsic thrombin generation |
| Fenu L. |
- |
G20210A prothrombin mutation and factor V Leiden (G1691A) to address local health policy |
| |
- |
Fasting homocysteine levels in predicting post methionine loading test results |
| Fenu L. |
- |
G20210A prothrombin mutation and allele 4G of gene PAI-1 in deep vein thrombosis |
| Fenwick B. |
- |
Lepirudin (Refludan®) prevents shigatoxin-induced hemorrhagic colitis/hemolytic uremic syndrome |
| Fenyvesi T. |
- |
Inhibition of blood coagulation by ximelagatran in patients with a first episode of symptomatic acute deep venous thrombosis for prophylaxis of recurrent events |
| Fenyvesi T. |
- |
Anti-coagulant effects of direct thrombin inhibitors: compared for potential use in clinical practice |
| Fenyvesi T. |
- |
Prophylaxis of recurrent thromboembolism in a patient with a history of heparin-induced thrombocytopenia with thrombosis, anti-lepirudin antibodies after Bjork-Shiley aortic valve implantation using fondaparinux |
| |
- |
Treatment of patients with a history of heparin-induced thrombocytopenia (HIT type II) and of anti-lepirudin antibodies with argatroban or lepirudin |
| Fenyvesi T. |
- |
Impact of direct thrombin inhibitors on actions of vitamin K antagonists on analysis with different coagulation parameters: aPTT and PT for argatroban, hirudin and melagatran |
| Ferlito C. |
- |
The platelet glycoprotein IIb/IIIa receptor antagonist c7E3Fab inhibits the coagualation activation in patients undergoing to percutaneous transluminal coronary angioplasty (PCTA) |
| |
- |
Desmopressin subcutaneous administration enhances platelet response ‘in vivo’ to Platelet-Activating Factor (PAF) and causes a rise in interleukin-6 plasma levels in haemophilia A and von Willebrand disease type I |
| Fernandes P. S. M. |
- |
Markers of hypercoagulability in Brazilian patients with DVT undergoing oral anti-coagulation therapy |
| Fernandes A. P. S. M. |
- |
Hemostatic parameters in Brazilian asymptomatic carriers of Factor V Leiden, prothrombin (G20210A) and methylenetetrahydrofolate reductase (C677T) mutations |
| Fernandez J. A. |
- |
Protein S confers neuronal protection during ischemic/hypoxic injury in mice |
| Fernandez J. A. |
- |
Activated protein C (APC) blocks p53-mediated apoptosis in ischemic human brain endothelium through endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) |
| Fernandez J. A. |
- |
Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model |
| Fernandez J. A. |
- |
Neutral and charged lipids in factor Va inactivation |
| |
- |
In vivo activated protein C (APC) neuroprotective activity involves endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) |
| Fernandez L. |
- |
Proteolytic pattern in advanced atherosclerotic human lesions: relation to vascular bed, plaque features, and cardiovascular risk factors |
| Fernandez De Velasco J. |
- |
Hypercoagulability in cerebrovascular disease (CD): factor V Leiden, prothrombin G20210A and MTHFR C677T mutations and polymorphism in the annexin V kozac sequence |
| Fernández De Velasco J. |
- |
Retrospective analysis of heritable thrombophilia in 90 children with Legg-Perthes disease |
| Fernandez De Velasco J. |
- |
TNF-alpha promoter polymorphisms (-238 and -308) in patients with cerebrovascular disease |
| Ferolla P. |
- |
Impairment of fibrynolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients |
| Ferrando F. |
- |
The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene reduces the risk of venous thromboembolism in carriers of the factor V Leiden mutation |
| |
- |
The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR |
| Ferrão L. |
- |
Molecular basis of inherited anti-thrombin deficiency in Portuguese families: identification of underlying molecular defects and screening for additional thrombotic risk factors |
| Ferrara D. E. |
- |
Inhibitors of NFkB and p38 kinase abrogate tissue factor up-regulation by anti-phospholipid antibodies |
| |
- |
Effects of fluvastatin on up-regulation of tissue factor by antiphospholipid antibodies |
| Ferrara R. |
- |
Acquired platelet dysfunction with eosinophilia in children: A tropical disease present in Venezuela |
| Ferrard-Sasson G. |
- |
Interest of diluted Russel viper venom time (dRVVT) in determining “pathogenic” lupus anticoagulants |
| Ferraresi P. |
- |
Factor VII polymorphisms and the risk of myocardial infarction in coronary atherosclerosis |
| |
- |
Heterogeneous molecular pattern of Factor VII deficiency associated to cerebral hemorrhage |
| Ferrari I. C. |
- |
Anti-thrombotic effect of combination of low molecular weight heparin with low doses of unfractionated heparin in experimental venous thrombosis |
| Ferrazzani S. |
- |
Inherited thrombophilia and associated risk for unexplained fetal loss |
| Ferreira J. |
- |
Phenotype of T cells in human abdominal aortic aneurysm |
| Ferreira M. F. R. |
- |
Markers of hypercoagulability in Brazilian patients with DVT undergoing oral anti-coagulation therapy |
| Ferreira A. C. P. |
- |
A transcobalamin gene polymorphism and the risk of deep venous thrombosis |
| |
- |
A 23-bp insertion in the EPCR gene and the risk of venous thrombosis |
| Ferrell J. |
- |
Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study |
| Ferrell G. |
- |
Prognostic value of activated protein C levels in patients with severe sepsis |
| Ferroni P. |
- |
In vivo platelet activation is associated to increased plasma levels of vascular endothelial growth factor – effects of aspirin treatment |
| Ferroni P. |
- |
Soluble CD40 ligand (sCD40L) plasma levels in nonsmall cell lung cancer |
| Feuerstein G. Z. |
- |
Orally active integrin antagonists perturb aIIbb3 integrin conformation |
| Ffrench P. |
- |
Two electrophoretic fibrinogen variants found in patients with normal coagulation and familial thrombosis |
| |
- |
Anti-thrombotic treatment after coronary artery bypass graft surgery (CABGS):economic consequence of a change in regimen |
| Fiessinger J.-N. |
- |
Bilateral deep-vein thrombosis and cancer: prospective study of 103 patients |
| Fiessinger J. N. |
- |
Factor II 20210 G-A but not Factor V Arg506Gln gene polymorphism is associated with peripheral arterial disease in a case-control study |
| Figueiredo M. S. |
- |
Use of a decision-making system based on the Fuzzy sets theory applied to the routine of results' release in the haemostasis laboratory: how to do it better and quicker |
| |
- |
Effects of isolated and combined use of ticlopidine, clopidogrel and aspirin on platelet function as evaluated by platelet aggregometry |
| |
- |
Comparative analysis of methods for detection of Activated Protein C resistance: an analysis of 755 consecutive patients |
| Figuera A. |
- |
Sickle cell disease, vascular endothelium dysfunction, abnormal endothelin-1 release, interleukin-6 plasma level, hyperhomocysteinaemia and thromboembolic risk |
| Figura S. |
- |
A new protocol for inhibitor elimination in high responding hemophilia A patients |
| Fijnheer R. |
- |
Novel approaches to determine the characteristics of ADAMTS13 inhibitors in patients with acquired TTP |
| |
- |
The sensitivity and specificity of ADAMTS13 activity for primary thrombotic thrombocytopenic purpura |
| |
- |
Elevated levels of d-dimer and fragment 1 + 2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis |
| Fijnvandraat K. |
- |
Incidence and risk factors for factor VIII antibodies in mild hemophilia A |
| |
- |
A mouse model for inhibitor development in mild hemophilia A |
| |
- |
Impact of knowledge of a positive family history on the clinical presentation of hemophilia |
| Filanovskaya L. I. |
- |
Different risk of pulmonary embolism development in patients with deep-vein thrombosis from North-Western Russia having either factor V Leiden or prothrombin G20210A mutation |
| |
- |
Venous thromboembolism in North-western Russia and genetic polymorphisms |
| Filion M. L. |
- |
Effects of full and partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II on the inhibition of thrombin and activated protein C |
| Filipiak K. J. |
- |
Activity of endogenous fibrinolytic system induced by exercise ECG test in patients with previous positive ECG-exercise test but without essential atherosclerotic changes in coronaries during angiography |
| Filippidis M. |
- |
Left adrenal hemorrhage with intravascular coagulation- case report |
| Filippucci E. |
- |
A comparison between routine plasma INRs and fingerstick whole blood INRs determinations, using three portable self-testing devices (Coagucheck®, Pro-Time®, Gem-PLC®) and a near-patient whole blood device (Thrombotrack®) |
| Filippucci E. |
- |
Management of oral anticoagulant therapy with Thrombotest® using a whole blood testing device (Thrombotrack®) in comparison to routine laboratory PT |
| |
- |
Activation of blood coagulation in patients undergoing perioperative blood salvage and reinfusion of no-washed whole blood after total knee arthroplasty |
| Filippucci E. |
- |
Oral anti-coagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) |
| Fimbel B. |
- |
Inherited risk factors are different in pregnant and nonpregnant women with venous thromboembolism |
| |
- |
G20210A prothrombin gene mutation appears as the most important inherited prothrombotic risk factor in ‘idiopathic’ portal vein thrombosis |
| Fimognari F. |
- |
Fibrinogen as predictor of ischemic stroke in patients with nonvalvular atrial fibrillation |
| Finazzi G. |
- |
A randomized clinical trial of oral anticoagulant therapy in patients with the antiphospholipid syndrome: the WAPS study |
| Findlay G. |
- |
The efficacy of standard dose vs. 30 mL kg-1 FFP in correcting laboratory parameters of hemostasis in critically ill patients |
| Finely J. M. |
- |
Factors that influence the prescribing of low-molecular-weight heparins (LMWHs) in community hospitals: opinions of physicians, clinical pharmacists, and formulary committee members |
| Fink C. A. |
- |
IgG antiphosphatidylserine and anti-b2GPI are better predictors of arterial and venous thrombosis than anticardiolipin antibodies in antiphospholipid syndrome |
| |
- |
Increased thrombin–anti-thrombin III levels in pre-eclampsia and disseminated intravascular coagulation |
| Finkelstein J. |
- |
Home-automated telemanagement affects quality of life in patients on anti-coagulation therapy |
| Finn A. |
- |
Variation in plasminogen activator inhibitor-1 gene and risk of meningococcal disease |
| Fiore L.D. |
- |
The Veterans Affairs Cooperative Studies Program's ‘80+ Hemorrhagic Cohort Study |
| Fiore M. M. |
- |
Control of Factor Xa activity by heparin in plasma is related to the inhibition of free Factor Xa |
| |
- |
Platelet factor 4 (PF4) neutralizes heparan sulfate-dependent inactivation of factor Xa by preventing enzyme interaction with polysaccharide |
| Fischer K. |
- |
Effects of bleeds on health-related quality of life in patients with hemophilia |
| Fischer A.-M. |
- |
Functional consequences of a factor VII gene donor splice site mutation causing a lethal factor VII deficiency: regulation in the splice site selection |
| Fischer T. H. |
- |
The development of pro-hemostatic lyophilized platelets with minimized risk for intravascular coagulation |
| Fischer K. |
- |
The relation between clinical phenotype and genotype of severe hemophilia A |
| Fischer T. H. |
- |
Bleeding phenotype and decreased viability in rap1b knockout mice |
| Fischer A. M. |
- |
A new co-operative effect of low molecular weight polysaccharides and cell surface heparin sulfate in enhancing bFGF-induced endothelial cell differentiation |
| Fish R. |
- |
High-level transgene expression of lentivirus-transduced human endothelial cells |
| Fish R. |
- |
Structural elements in tissue-type plasminogen activator contributing to its storage in primary endothelial cells |
| Fish R. |
- |
Effect of simvastatin on the production of tissue-type plasminogen activator in endothelial cells |
| Fisher T. A. |
- |
Comparative response of plasma VWF in normal and von Willebrand disease dogs to up-regulation of VWF mRNA by Interleukin-11 vs. Weibel–Palade body release by Desmopressin (DDAVP) |
| Fisher L. |
- |
Congenital factor VII deficiency and thrombosis. Description of a novel mutation |
| Fisher C. M. |
- |
A prospective randomized trial of anti-platelet therapies in patients with carotid artery disease (preliminary results) |
| Fitches A. C. |
- |
Variation in antithrombin helix A impedes secretion and function of the inhibitor |
| Fitches A. |
- |
The anti-thrombin variant -6Arg is a silent mutation |
| Fitz Maurice M. |
- |
Safety considerations of Enoxaparin as an alternative to oral anti-coagulants in high risk cardioembolic patients with a programed surgical procedure. SWITCH trial |
| Fitzgerald D. J. |
- |
Proteomic analysis of proteins secreted by platelets |
| Fitzgerald D.J. |
- |
Integrin aVb3 dependent adhesion and spreading under shear stress is particular dependent on the two phenylalanines in the highly conserved GFFKR-region |
| Fitzgerald D. J. |
- |
Integrin aVb3 dependent adhesion and spreading under shear stress is particular dependent on the two phenylalanines in the highly conserved GFFKR-region |
| Fitzgerald D. |
- |
Platelet proteomics |
| Fitzgerald D. J. |
- |
Evaluating 'aspirin resistance' in a population with cardiovascular disease |
| Fitzgerald D. |
- |
The choice of assay, agonist and anticoagulant for determining efficacy of GPIIb/IIIa antagonists |
| Fitzgerald D. J. |
- |
An analysis of the platelet transcriptome using commercial microarrays |
| Fitzmaurice D. |
- |
An evaluation of four methods of external quality assurance (EQA) for patient self-management (PSM) of oral anti-coagulation: report on 97 patients |
| Flak A. |
- |
Factor V Leiden and blood coagulation at the site of microvascular injury in coumadin treated patients and healthy control |
| Fleming C. |
- |
Coagulation factor content of solvent/detergent plasma compared to fresh frozen plasma |
| Fletcher J. |
- |
Venous thromboembolism and fractured neck or femur |
| Fletcher S. |
- |
The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke |
| Flood E. |
- |
Health-related quality of life in adults with hemophilia: the patient perspective |
| Florain-Kujawski M. |
- |
Heparin derived oligosaccharides are capable of passing through the blood brain barrier: experimental evidence in a rat model |
| Flores N. |
- |
Deficiency in one Gas6 receptor (Axl, Sky or Mer) protects mice against thrombosis because of a platelet dysfunction |
| Florguin S. |
- |
Blood-borne tissue factor aggravates the outcome of endotoxemia |
| Florian-Kujawski M. |
- |
Molecular-weight dependence on the inhibition of procarboxypeptidase U by heparin and a polydeoxyribonucleotide derived antithrombotic agent (Defibrotide) |
| |
- |
Inhibition of procarboxypeptidase U by tinzaparin. A potential mechanism of its profibrinolytic actions |
| Florian-Kujawski M. |
- |
Heparinase I digestion of tinzaparin: a novel approach to neutralize the anti-coagulant and potential hemorrhagic effects of low molecular weight heparin |
| Florian-Kujawski M. R. |
- |
Elevated soluble thrombomodulin levels in patients with acute coronary syndrome: down-regulation by anticoagulant dosage of low molecular weight heparins |
| Florian-Kujawski M. |
- |
Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis |
| Florian-Kujawski M. |
- |
Non-coagulant variants of thrombin are capable of activating procarboxypeptidase U |
| Florian-Kujawski M. R. |
- |
Polypharmacologic actions of low-molecular-weight heparins: lessons from clinical trials |
| |
- |
Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications |
| Florian-Kujawski M. |
- |
Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins |
| Florquin S. |
- |
Plasminogen activator inhibitor type I-deficient (PAI–/–) mice show an improved early host defense in E. coli peritonitis by a neutrophil-dependent mechanism |
| Fogato L. |
- |
The G>T point mutation (Val34Leu) in the Factor XIII-A subunit gene in venous leg ulcers |
| Foidart J. M. |
- |
Plasminogen activator inhibitor PAI-1 as a regulator of urokinase in angiogenesis |
| Foka Z. |
- |
High frequency of factor V Leiden and prothrombin G20210A mutations in Greek hemophiliacs |
| Foley V. |
- |
Inhibition of platelet secretion-induced neutrophil activation by ELR peptide derivatives |
| Foli C. |
- |
Prolonged APTT children undergoing elective tonsillectomy |
| |
- |
Anti-protein S antibodies in patients with venous and/or arterial thrombosis |
| Follows G. A. |
- |
Human endothelial cell protein C receptor (EPCR) expression: role of proximal and distal 5'-gene regulatory elements |
| Fong Y. F. |
- |
Coagulation and fibrinolysis during the menstrual cycle and the effects of increased body mass index |
| Fong T. H. |
- |
Comparison of the binding character of triflavin on resting and activated aIIbb3 integrin in human platelets by electron microscopy |
| Fong S. Z. |
- |
Clinical profile of rare coagulation disorders in an Asian population |
| Font J. |
- |
Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome |
| |
- |
Polymorphisms of platelet glycoproteins Ib-a and Ia/IIa: relationship with early arteriosclerosis and arterial thrombosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus |
| Fontaine S. |
- |
Measurement of synthetic pentasaccharide fondaparinux (arixtra) anti-Xa activity |
| Fontaine V. |
- |
Smooth muscle cell recolonization of the aneurysmal thrombus is prevented by storage of leukocyte elastase in fibrin matrix |
| Fontaine S. |
- |
Normal values of total and free TFPI levels in the newborn and in children |
| Fontaine J.-M. |
- |
Functional pan-universality of the age-related regulatory elements ASE and AIE, and development of age dimension technology |
| Fontana S. |
- |
Splenectomy in relapsing and plasma-refractory thrombotic thrombocytopenic purpura |
| Fontana P. |
- |
Factor II 20210 G-A but not Factor V Arg506Gln gene polymorphism is associated with peripheral arterial disease in a case-control study |
| Fontana S. |
- |
Observations on immunoadsorption (IA) as an auxiliary therapy for acquired thrombotic thrombocytopenic purpura (TTP) |
| Fontana P. |
- |
Tissue Factor-603 A–G promoter polymorphism is associated with human monocyte constitutive but not with LPS induced gene expression |
| Fontana G. |
- |
Genetically defined protein S (PS) deficiency is associated with venous thrombosis |
| Fontana P. |
- |
ADP-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects |
| Fontcuberta J. |
- |
Heritability of plasma antiphospholipid antibodies |
| |
- |
Transmission electron microscopy of granulocyte inclusions in genetically confirmed MYH9-related disorders |
| |
- |
Complexity of the genetic contribution to Factor VII deficiency in two Spanish families: clinical and biological implications |
| |
- |
Risk of ischemic stroke (IS) associated with plasma levels of thrombin-activatable inhibtor fibrinolysis (TAFI) |
| |
- |
The 46C®T polymorphism in F12 gene is a risk factor for coronary artery disease |
| |
- |
Factor VII plasma levels and the F7 structural gene: complete dissection of a human quantitative trait locus |
| |
- |
Self-management of oral anti-coagulation reduces the incidence of complications: preliminary results of the ACOA clinical trial |
| |
- |
Genetic coregulation of C4b-binding protein (C4BP) and free Protein S plasma levels: a link between complement and hemostasis |
| |
- |
A quantitative trait locus on chromosome 11 is the major genetic determinant of homocysteine plasma levels. Results from the GAIT Project |
| |
- |
Incidence of venous thrombosis in carriers of familial thrombophilia with a personal history of venous thrombosis |
| |
- |
The 46C®T polymorphism in the F12 gene as a risk factor for venous thrombosis: association after linkage analysis |
| |
- |
Functional re-sequencing of the factor VIII (f-VIII) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-VIII activity levels in the Gait Project |
| |
- |
Genetic dissection of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| |
- |
A genome-wide scan for genetic loci influencing levels of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| |
- |
Functional resequencing of the factor IX (f-IX) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-IX activity levels in the GAIT project |
| |
- |
The 46C®T polymorphism in the F12 gene is a risk factor for ischemic stroke |
| Fontenay M. |
- |
Human platelet microparticles shedding is independent of the Cdc42/Rac1/PAK Pathway |
| Fontes F. S. |
- |
Use of a decision-making system based on the Fuzzy sets theory applied to the routine of results' release in the haemostasis laboratory: how to do it better and quicker |
| for the Estrogen and Thromboembolism Risk (ESTHER) Study Group |
- |
Oral not transdermal estrogen replacement therapy is associated with venous thromboembolism risk |
| For The LITE Investigators† |
- |
A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer |
| for the PROTECT Trial Investigators¶ |
- |
Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement |
| for the Regimen Investigators |
- |
Clinical outcomes with the use of unfractionated heparin or low-molecular-weight heparin as perioperative bridging therapy in patients on long-term oral anti-coagulants: Rationale, objectives, and design of a large, long-term study (REGIMEN) |
| Forastiero R. |
- |
Inherited and acquired prothrombotic risk factors in women with early or late pregnancy losses |
| |
- |
Differences in Th1- and Th2-like cytokine patterns between patients with antiphospholipid syndrome and with lepromatous leprosy-related aPL |
| |
- |
Autoantibodies to TFPI are associated with definite APS but not with infection-related aPL |
| Forastiero R. |
- |
Evaluation of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) plasma levels and the in vitro inhibition of activated factor X by PZ/ZPI in patients with autoimmune aPL |
| Forbes A. |
- |
Randomized trial of tinzaparin, a low molecular weight heparin (LMWH) vs. placebo in the treatment of mild-to-moderately active ulcerative colitis |
| Forcella M. |
- |
Occurrence of myocardial infarction and PAI-1 4G/5G and ACE I/D gene polymorphisms in patients on chronic dialysis |
| Ford I. |
- |
The phagocytic capacity of human endothelial cells in culture for apoptotic endothelial cells is inhibited by IgG from patients with anti-phospholipid antibodies |
| |
- |
The CAVA study: a double-blind randomized controlled trial of clopidogrel and aspirin vs. aspirin alone in patients with intermittent claudication undergoing peripheral percutaneous transluminal angioplasty |
| Ford I. |
- |
Enhanced in vivo platelet activation in patients with peripheral arterial disease, and differences between intermittent claudication and critical limb ischemia |
| Ford E. |
- |
Elevated factor VIIIC level is a major risk factor for venous thrombo-embolism in the black population |
| Ford I. |
- |
Procoagulant changes in human macrophages induced by environmental microparticles [PM10]: a possible pathogenetic mechanism in cardiovascular disease |
| |
- |
Evidence of transient endothelial activation in patients in sinus rhythm after electrical cardioversion of persistent atrial fibrillation |
| Fornaciari G. |
- |
Hyperhomocysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease |
| Forner R. |
- |
Heritability of plasma antiphospholipid antibodies |
| |
- |
Risk of ischemic stroke (IS) associated with plasma levels of thrombin-activatable inhibtor fibrinolysis (TAFI) |
| Forsberg A. |
- |
‘Video Grand Rounds’: an assessment of internet based grand rounds to increase collaboration between comprehensive hemophilia treatment centers |
| Forslund M. |
- |
Acute hyperglycemia enhances platelet secretion but not platelet aggregation |
| Fortenberry Y. |
- |
Role of surface amino acid residues in thrombin essential for inhibition by antithrombin, heparin cofactor II and protein C inhibitor |
| |
- |
Effect of a RNA-thrombin aptamer on thrombin inhibition by antithrombin, heparin cofactor II and protein C inhibitor |
| Fortuna S. |
- |
The incidence of venous thromboembolism in double-heterozygous carriers of antithrombin, protein C and protein S deficiency and HR2 haplotype |
| Fosbinder T. |
- |
Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study |
| Foster P. R. |
- |
Removal of a BSE-derived agent by ion exchange chromatography used in the manufacture of a high purity factor VIII concentrate |
| Foster T. J. |
- |
Evidence for a serum protein mediating Staphylococcus aureus induced platelet aggregation |
| Fouda M. |
- |
Elevated Serum Nerve Growth Factor (NGF) levels in patients with acute leukemia and lymphoma especially with CNS involvement |
| Foulis P. R. |
- |
Relationship of thromboembolism (TE) to subsequent cancer diagnosis: a study in a veteran population |
| Fourdrain A. |
- |
The biphasic waveform of APTT optical clot formation profile is related with the activation of FVII but not with ISTH DIC score or classical coagulation activation parameters |
| Fox S. C. |
- |
Effects of ADP-antagonists on platelet calcium mobilization in acute coronary syndrome patients |
| Fox J. E. B. |
- |
Regulation of megakaryocyte polyploidization and platelet release by the cytoplasmic tail of glycoprotein Iba |
| Fox S. C. |
- |
P2Y12 antagonists interact with agents that stimulate adenylate cyclase to inhibit calcium mobilization responses in platelets |
| Fox M. L. |
- |
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Fox S. |
- |
The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke |
| Frøland S. S. |
- |
Interleukin-7-mediated inflammation in unstable angina – possible role of chemokines and platelets |
| Fraccarollo D. |
- |
Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition – role of platelet VASP phosphorylation |
| |
- |
Novel role for the membrane-bound chemokine fractalkine as a pathophysiologically relevant mechanism in platelet activation and adhesion |
| Fraga M. |
- |
Non-Hodgkin's lymphoma and antiphospholipid antibodies. Are they surrogate markers for relapse? |
| Fraga M. |
- |
Effects of cardiopulmonary bypass on platelet activation markers |
| Fragia K. |
- |
Early therapeutic splenectomy may reduce morbidity and management costs in selected resistant or relapsing cases of TTP/HUS |
| Frampton J. |
- |
PLCg2-independent activation of integrins by GPVI: involvement of PLCg1 and PI3-kinase |
| |
- |
Murine (m) aIIb out-competes human (h) aIIb for mouse b3 in a transgenic mouse model: Implications for integrin subunit interactions |
| |
- |
Integrin a2b1 stimulates platelet spreading through protein tyrosine phosphorylation and calcium mobilization |
| Franchi F. |
- |
Intruterine Growth Restriction (IUGR) and thrombophilic polymorphisms |
| Franchini M. |
- |
Efficacy of Haemate P in the management of patients with von Willebrand disease undergoing surgery |
| Francis J. L. |
- |
Identification of a tissue factor ortholog in zebrafish, a potential new animal model of hemostasis and cancer |
| Francis C. W. |
- |
FGF-2 but not FGF-1 binds fibrin and supports long-term endothelial cell growth |
| Francis C.W. |
- |
Rates of recurrent thromboembolism and bleeding in venous thromboembolism patients treated with long-term LMWH |
| Francis J. |
- |
Heparin Induced Thrombocytopenia as it relates to emergency room issues |
| Francis C. W. |
- |
Ultrasound improves myocardial perfusion in a canine model of myocardial infarction |
| |
- |
Low intensity ultrasound increases endothelial cell nitric oxide synthase activity |
| Francis J. L. |
- |
Tissue factor is present in platelet-derived microparticles from healthy donors |
| |
- |
Platelet purified vascular endothelial growth factor-165 enhances tumor cell tissue factor expression and procoagulant activity |
| Francis J. |
- |
Trends in incidence and diagnosis of heparin-induced thrombocytopenia at a tertiary medical center |
| Francis J. L. |
- |
Functional anti-heparin-PF4 antibody-mediated platelet–endothelial cell interactions: modulation of tissue factor activity involved in the HIT pathogenesis |
| Francis J. |
- |
Bivalirudin, a direct thrombin inhibitor, in the treatment of heparin-induced thrombocytopenia |
| |
- |
Impact of reagent choice on the APTT response to argatroban |
| |
- |
The importance of repeat laboratory testing in the diagnosis of heparin-induced thrombocytopenia |
| Francis C. W. |
- |
Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) |
| Francis J. L. |
- |
Platelet CD40L and CD40 enhance tumor cell-induced coagulopathy and experimental metastasis |
| Francis J. |
- |
Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis |
| Francis J. L. |
- |
Haemoglobin induces the production and release of matrix metalloproteinase-9 from human malignant cells |
| Francis C. W. |
- |
FGF-2 binds to fibrinogen fragment D1 and prevents degradation to fragment D2 |
| |
- |
Structural basis for differences in heparin-dependence of endothelial cell proliferative activities of human FGF-1 and FGF-2 |
| |
- |
Molecular weight dependent heparin inhibition of endothelial cell stimulation by FGF-2 and VEGF |
| Francis J. L. |
- |
Bovine heparin results in higher generation of functional anti-heparin-PF4 antibodies than porcine heparin following coronary artery bypass surgery |
| Franco R. F. |
- |
Effects of isolated and combined use of ticlopidine, clopidogrel and aspirin on platelet function as evaluated by platelet aggregometry |
| |
- |
Thrombotic risk in first-degree relatives of factor V Leiden (FVL) and factor II G20210A carriers |
| |
- |
Factor XIII (FXIII) Val34Leu, His95Arg and G30899A polymorphisms and the risk of deep venous thrombosis |
| Franco R. F. |
- |
Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis |
| |
- |
Use of a decision-making system based on the Fuzzy sets theory applied to the routine of results' release in the haemostasis laboratory: how to do it better and quicker |
| |
- |
A 23-bp insertion in the EPCR gene and the risk of venous thrombosis |
| |
- |
A transcobalamin gene polymorphism and the risk of deep venous thrombosis |
| Franco R. F. |
- |
Comparative analysis of methods for detection of Activated Protein C resistance: an analysis of 755 consecutive patients |
| Franco R. F. |
- |
Procoagulant effects of raloxifene in postmenopausal women |
| |
- |
Psychologic impact of thrombophilia screening in asymptomatic relatives of carriers of prothrombotic mutations |
| Franco R. F. |
- |
Polymorphisms in the 3'-untranslated region of the TAFI mRNA modulate TAFI gene expression through control of mRNA stability |
| |
- |
A functional single-nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) associated with risk and outcome of meningococcal disease (MD) |
| Frank J. |
- |
Expression and function of platelet glycoproteins in newborns and adults |
| Franz F. |
- |
Different thromboprophylaxis approaches in patients undergoing knee arthroscopy (KANT study): interim report of prospective randomized study |
| Franz R. |
- |
The use of the rotational thrombelastograph (ROTEG) in the quantification of the ‘lytic state’ during thrombolytic therapy: a comparative analysis in the subhuman primate |
| Franz G. |
- |
Anti-inflammatory mechanisms of PS3, a new drug candidate with both anti-inflammatory and anti-thrombotic activities |
| Franzoni M. |
- |
Clinical quality assessment program for the oral anti-coagulant clinic: preliminary report of a multicentric Italian exercise |
| Franzoni C. |
- |
Clinical and laboratoristic performance evaluation of three point-of-care devices for INR determination (Coagucheck, ProTime, Harmony) |
| Frapaise X. |
- |
Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis |
| Frasa W. L. H. |
- |
Two sensitive chromogenic assays of fondaparinux sodium (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in plasma |
| |
- |
Two sensitive chromogenic assays of fondaparinux sodium (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in plasma |
| Fraser A. G. |
- |
Warfarin-resistant factor VII is a potential risk factor for thromboembolism (TE) after prosthetic heart valve replacement |
| Frass M. |
- |
Treatment of adults with sepsis-induced coagulopathy and purpura fulminans with a plasma-derived protein C concentrate (Ceprotin®) |
| Fratu C. |
- |
Platelet adhesion index and soluble E-selectin in the prediction of cardiovascular risk |
| |
- |
Platelet-mediated vasodilatation factor activated by Zinc on diabetic rats |
| Freay A. |
- |
Overexpression of PAI-1 prevents abdominal aortic aneurysm development |
| Frebelius S. |
- |
Influence of intraluminal thrombus on cellular and structural features of the aneurysm wall |
| Fredenburgh J. |
- |
GH9001, a novel anti-thrombotic agent, is more effective than low-molecular-weight heparin, fondaparinux, or hirudin in rabbit models |
| Fredenburgh J. C. |
- |
gA/g' fibrin affords thrombin greater protection from inhibition by the heparin/antithrombin complex than gA/gA fibrin |
| Freedman J. |
- |
Autoantibodies to recombinant PSI domain but not to cytoplasmic tail of beta3 integrin cause immune thrombocytopenia |
| |
- |
PAR-1 (1–41) and SFLLRN independently propagate platelet activation |
| FreeDman J. |
- |
Procoagulant surface expression on activated human platelets persists despite increased aminophospholipid translocase activity |
| Freedman J. |
- |
Extension of human platelet storage up to 7–8 days does not reduce their in vivo viability in a rabbit model |
| |
- |
Senescent rabbit platelets, or rabbit platelets with experimentally shortened survival, are apoptotic with increased surface exposure of procoagulant phosphatidylserine (PS) |
| Freeman R. |
- |
Factor VII levels, coronary artery disease, and MI |
| Freeman M. S. |
- |
Plasma leptin is associated with hemostatic cardiovascular risk factors |
| Freeman D. J. |
- |
The G>T point mutation in codon 34 of the factor XIII gene and the risk of pre-eclampsia |
| Freestone B. |
- |
Endothelial damage in congestive heart failure (CHF): relationship between circulating endothelial cells (CECs) and von Willebrand factor (vWf) |
| Freestone B. |
- |
Which is the ideal plasma marker of endothelial damage/dysfunction in atrial fibrillation? A comparison of von Willebrand factor, E-selectin and soluble thrombomodulin |
| Fregin A. |
- |
Mutations in genes of the gamma-glutamyl carboxylase and the vitamin K epoxidase reductase complex are responsible for the phenotype of hereditary combined deficiency of vitamin K-dependent clotting factors |
| Freier J. |
- |
The impact of GPIIb-IIIa and GPIa-IIa polymorphisms on the adhesion of platelets to collagen and fibrinogen in a microtiter-plate adhesion system under static and dynamic conditions |
| Frelinger A. L. |
- |
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| French D. L. |
- |
Biochemical, immunologic and computer-modeling evidence localizing the mAb 7E3 Epitope on aIIbb3 |
| Frenkel E. P. |
- |
Evaluation of platelet function analyzer (PFA-100), whole blood (WB), and platelet rich plasma (PRP) aggregation methods in detecting aspirin resistance |
| |
- |
Correlation of supra-therapeutic (ST) International Normalized Ratio (INR) with vitamin-K-dependent factors (VKDF) |
| Frenkel E. J. |
- |
Development of a biosensor system for self-testing the intensity of anti-coagulation by anti-coagulated patients in capillary whole blood |
| Freson K. |
- |
The Gs agonist PACAP(1–38) is a physiological inhibitor of platelet aggregation and megakaryocyte maturation |
| |
- |
Functional polymorphisms in the paternally expressed XLas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation resulting in platelet Gs hyperfunction |
| Fressinaud E. |
- |
Evaluation of automated measurement of ristocetin cofactor activity of von Willebrand factor on STA-R® in von willebrand disease: study in 154 patients |
| |
- |
Mutation of cysteines 1157 or 1234 located within the D3 domain of Von Willebrand Factor causes intracellular retention of high molecular weight multimers |
| |
- |
Identification and expression of the first type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene |
| |
- |
Type 2N von Willebrand disease due to compound heterozygosity for the frequent R854Q type 2N mutation and a new R763G mutation abolishing the cleavage of von Willebrand factor propeptide |
| |
- |
Analytical validation of the automated measurement on STA-R of the ristocetin cofactor activity (VWF:RCo) of von Willebrand factor |
| |
- |
Identification of seven new candidate mutations of ADAMTS13 gene in four French families related to congenital thrombotic thrombocytopenic purpura |
| Fretigny M. |
- |
Protein C promoter polymorphisms are potential additional risk factors for cerebral venous thrombosis |
| |
- |
Thrombophilic risk factors and idiopathic sudden sensorineural hearing loss |
| |
- |
Frequency and effects of cytochrome P450 2C9 polymorphisms in 61 patients treated by warfarin |
| |
- |
Prethrombotic biological markers in congenital thrombophilic patients. Preliminary results of a randomized long-term secondary prophylaxis study using warfarin and comparing two INR target ranges |
| Freund M. |
- |
A key role of the fast ATP-gated P2 X 1 cation channel in the thrombosis of small arteries in vivo |
| |
- |
PLC g-dependent GPIb signaling following platelet adhesion to von Willebrand factor through a pathway distinct from FcR g chain and FcgRIIA |
| |
- |
The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser-induced model of arterial thrombosis in vivo |
| |
- |
A key role of the fast ATP-gated P2X1 cation channel in the thrombosis of small arteries in vivo |
| |
- |
Evidence for a PLCg2-independent alpha2beta1-triggered signalling pathway contributing to platelet aggregation in response to collagen |
| Freyaldenhoven B. |
- |
Genetic profiling of 20 patients with FVII deficiency by dHPLC and sequence analysis: detection of 7 novel mutations |
| Freyburger G. |
- |
LPS-activation of THP-1 cells: effect of anti-thrombin studied by in vivo footprinting of the tissue factor (TF) gene promoter |
| Freyburger G. |
- |
The thrombin generation test (TGT) may be a predictive parameter for thrombus formation during endovascular embolization of cerebral aneurysms |
| |
- |
In vitro and ex vivo study of the effects of core pentasaccharide and of longer heparin chains on latent antithrombin (AT) |
| Freyssinet J. M. |
- |
The role of the ATP-Binding Cassette transporter A1 (ABCA1) in phosphatidylserine cell surface exposure and in the modulation of the procoagulant phenotype |
| |
- |
A new evidence of a relationship between store-operated calcium entry and the regulation of procoagulant phosphatidylserine exposure at the surface of stimulated cells |
| |
- |
The coordinated transcription of genes encoding regulators of cell cycle progression revealed by expression profiling upon calcium ionophore A23187 treatment of B lymphoblasts from a patient with Scott syndrome |
| Freyssinet J. M. |
- |
Cellular microparticles, what are they bad or good for? |
| Freyssinet J. M. |
- |
Importance of beta-2 glycoprotein I in the lupus anticoagulant cofactor effect: a case report |
| Fribourg C. |
- |
Factor VIII – factor IX interactions probed by chimeric factor VIII/V variants: complex assembly and cofactor function involve different residues within the A3 domain region 1803–1818 |
| |
- |
Role of factor IX surface loop 342–347 in factor VIII-mediated enhancement of catalytic activity |
| Fribourg C. |
- |
Molecular events involved in factor IXa stimulation by the factor VIII A2 domain |
| Fridberg M. J. |
- |
Pharmacokinetics, pharmacodynamics and tolerability of single injections of activated recombinant FVII (rFVIIa, NovoSeven®) in healthy Caucasian and Japanese subjects |
| Fried L. P. |
- |
Intracellular adhesion molecule-1 is associated with cardiovascular disease in elderly men and women |
| Friedman K. D. |
- |
Type 2 M von Willebrand disease due to linked P1266Q and V1279I substitutions in the von Willebrand factor A1 domain |
| |
- |
Assay of the von Willebrand factor propeptide in patients with type 1 von Willebrand disease (VWD) and the identification of patients with a S2179F mutation in the D4 region of von Willebrand factor |
| Friedman R. |
- |
Prophylactic warfarin in clinical practice. Treatment intensity when warfarin is used to prevent VTE after major joint surgery: findings from the Global Orthopedic Registry (GLORY) |
| Friedman R. |
- |
Duration of prophylaxis for venous thromboembolism after total hip and knee arthroplasty: findings from the global orthopedic registry (GLORY) |
| Friedman K. D. |
- |
A case of compound type 2N/type 1 von Willebrand disease linked to a novel von Willebrand factor exon 18 mutation A2311G encoding for Met 771 val |
| Friedman R. |
- |
Concomitant use of mechanical and pharmacological methods of prophylaxis for venous thromboembolism after total hip and knee arthroplasty: Findings from the Global Orthopaedic Registry (GLORY) |
| Friedrich U. |
- |
Changed inactivation pathway of factor Va by activated protein C in the presence of heparin |
| Friedrich U. |
- |
In vitro effect of recombinant activated factor VII on thrombin generation and clot formation in blood from patients on vitamin K-antagonist therapy |
| Friedrich U. |
- |
Hemophilia patients and the assessment of thrombin generation in platelet-rich plasma and platelet-poor plasma |
| Friedrich R. |
- |
Mechanisms of conformational activation of prothrombin by staphylocoagulase and fibrinogen substrate recognition |
| Friedrich U. |
- |
In vivo monitoring of hemophilia A patients with inhibitors under recombinant factor VIIa therapy |
| Frigerio M. |
- |
Platelet-associated Tissue Factor: modulation of cell surface expression by platelet agonists |
| |
- |
Hemostasis and inflammation in advanced heart failure and after successful heart transplantation |
| |
- |
Platelet-associated Tissue Factor expression in patients with unstable coronary artery disease |
| Friso S. |
- |
Low vitamin B6, markers of inflammation, and coronary artery disease |
| Friso S. |
- |
Factor VII polymorphisms and the risk of myocardial infarction in coronary atherosclerosis |
| Fritsch P. |
- |
The effect of pretreatment with clopidogrel on platelet and coagulation activation in patients with stable angina undergoing elective coronary stenting |
| Fritts L. |
- |
A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy |
| Fritzen M. |
- |
Recombinant Lopap (a prothrombin activator from Lonomia obliqua) has a very conservative structure of lipocalins |
| Froehlich J. |
- |
A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) |
| Froesner G. |
- |
23 years experience with the pateurized factor VIII concentrate Beriate HS (Hemate HS) in pediatric patients and young adults |
| Frojmovic M. |
- |
Role of the affinity state of the a IIbb 3 receptor for fibrinogen in the formation and reversibility of model particle and platelet aggregation in shear |
| |
- |
Inter-individual variability in inhibition of platelet activation and aggregation by clopidogrel |
| Frojmovic M. |
- |
Primordial role of the P2Y12 ADP receptor in different phases of platelet–collagen interactions |
| Frojmovic M. |
- |
Both shear and temperature can profoundly alter antithrombotic drug efficacy: demonstration with the P2Y12 ADP receptor antagonist, ARC-69931MX |
| Frontroth J. P. |
- |
Biological and clinical DDAVP response in children with von Willebrand disease (VWD) |
| Frontroth J. |
- |
Arterial ischemic stroke (AIS) in children: a prospective 10-year registry in Argentina |
| |
- |
Venous thromboembolism (VTE) in children: A prospective 10-year registry in Argentina |
| |
- |
Cerebral sinovenous thrombosis (SVT) in children: a prospective 10-year registry in Argentina |
| Frossard M. |
- |
High prevalence of aspirin resistance in patients with acute coronary syndromes |
| Frost F. J. |
- |
Health care costs and clinical outcomes in patients on chronic oral anti-coagulation undergoing perioperative bridging with low-molecular-weight heparin vs. unfractionated heparin |
| Fruebis J. |
- |
CTRP1 – a vascular wall protein that can prevent platelet thrombosis without causing bleeding |
| Frulla M. |
- |
Below-knee elastic compression stockings for prevention of the post–thrombotic syndrome in patients with proximal-vein thrombosis: a prospective controlled randomized study |
| |
- |
The long-term clinical course of acute deep vein thrombosis of the arm: a prospective cohort study |
| Fu J. |
- |
Quantitative analysis of gene expression for vascular endothelial growth factor and its application |
| Fu M. S. |
- |
Clinical thrombolytic trial of a new type of tissue-plasminogen activator in patients with acute stroke |
| Fu J. |
- |
Establishment of urokinase receptor gene antisense RNA transfer system and its influence on uPAR expression in leukemia cells |
| Fucharoen G. |
- |
Detection of the factor XIIIA Val34Leu polymorphism in Thais |
| Fuchs I. |
- |
High prevalence of aspirin resistance in patients with acute coronary syndromes |
| Fuentes-Prior P. |
- |
Mechanisms of conformational activation of prothrombin by staphylocoagulase and fibrinogen substrate recognition |
| Fuernkranz A. |
- |
Oxidized phospholipids induce proatherogenic genes in murine carotid arteries |
| Fuglsang J. |
- |
Whole blood coagulation profiles in patients with thrombosis |
| Fujii J. |
- |
Shiga toxin interactions with platelets: differential effects of anti-coagulants and platelet isolation procedures |
| Fujii Y. |
- |
Crystal structure of a disintegrin from snake venom containing a cell adhesion recognition sequence RGD |
| Fujimoto Z. |
- |
Crystal structure of a disintegrin from snake venom containing a cell adhesion recognition sequence RGD |
| |
- |
Effect of Mg(II) ion on the interaction of factor IX with phospholipid membrane |
| Fujimura Y. |
- |
Localization and activity of ecto-ATP diphosphohydrolase/CD39 in human tissues |
| |
- |
Mechanism of decreased plasma von Willebrand Factor-cleaving metalloproteinase activity in patients with collagen vascular disease |
| |
- |
Mutations of ADAMTS13 gene in four Japanese families with Upshaw–Schulman syndrome |
| |
- |
D1596-R1668 of von Willebrand factor is a minimal region recognized as a specific substrate for ADAMTS-13 |
| Fukuda T. |
- |
DX-9065a, a direct factor Xa inhibitor prevents both arterial and venous thrombosis in rats via blocking prothrombinase complex activity – comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor |
| Fukuda K. |
- |
The hemostatic effectiveness of regular infusions of factor VIII concentrates in hemophilia A patients with high responder inhibitors |
| Fukudome K. |
- |
In vivo activated protein C (APC) neuroprotective activity involves endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) |
| |
- |
Endothelial protein C receptor (EPCR) is expressed in placental villi and cultured syncytiotrophoblasts |
| |
- |
Activated protein C (APC) blocks p53-mediated apoptosis in ischemic human brain endothelium through endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) |
| Fukunaga M. |
- |
Prediction of the organ dysfunctions by coagulation/fibrinolysis molecular markers at the beginning of sepsis |
| Fukutake K. |
- |
Roles of the individual g-carboxyglutamic acid residues of factor VII |
| Fulfaro F. |
- |
Chemotherapy-induced activation of hemostasis: the role of d-dimer |
| Fuller G. L. J. |
- |
Characterization of novel platelet and procoagulant activities from Bothrops cotiara snake venom |
| Fuller J. |
- |
Performance evaluation of the new CoaguChek® PT.S-test on the CoaguChek® S system |
| Fuller C. |
- |
An evaluation of four methods of external quality assurance (EQA) for patient self-management (PSM) of oral anti-coagulation: report on 97 patients |
| Fuller J. |
- |
Equivalence of venous and capillary INR values determined with the new CoaguChek® PT.S-test on the CoaguChek® S system |
| Fuller III E. |
- |
Acquired von Willebrand's disease not responding to Rituximab |
| Fulton J. |
- |
Dramatic improvement in the care and management of patients with DVT in a large UK hospital |
| Funck-Brentano C. |
- |
Variations of INR and Factor VII Level are linked to Cytochrome P450 2C9 genotype |
| Funk M. |
- |
Successful immune tolerance therapy in hemophilia B patients with fix: a new immunesuppressive strategy |
| Funk M. B. |
- |
Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors |
| Funk M. |
- |
Clinical manifestation and therapy in children with hereditary angioedema (HAE) – a prospective follow up |
| Furie B. |
- |
In vivo real time microscopy in a living mouse: A novel pathway of blood coagulation is mediated by microparticle PSGL-1 and platelet P-selectin |
| |
- |
FIX Gla Domain: Identification and characterization of residues involved in the phosphatidylethanolamine/phosphatidylserine phospholipid membrane interaction |
| Furie B. C. |
- |
FIX Gla Domain: Identification and characterization of residues involved in the phosphatidylethanolamine/phosphatidylserine phospholipid membrane interaction |
| Furie K. |
- |
Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS) |
| Furie B. |
- |
Time-dependent distribution of P-selectin in an arterial thrombus in vivo defines leukocyte rolling during thrombus formation |
| Furie B. C. |
- |
Time-dependent distribution of P-selectin in an arterial thrombus in vivo defines leukocyte rolling during thrombus formation |
| |
- |
Opposing effects of P-selectin and PECAM-1 on arterial thrombus growth and stability in vivo |
| Furie B. |
- |
Opposing effects of P-selectin and PECAM-1 on arterial thrombus growth and stability in vivo |
| Furie B. |
- |
Mechanisms of Gla domain membrane binding |
| Furihata K. |
- |
Convulxin binds to native, human glycoprotein Iba (GPIba) |
| |
- |
Impaired thrombus formation in a murine model of glycoprotein VI deficiency |
| Furman M. I. |
- |
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Furmedge J. |
- |
Reference ranges for hemostatic parameters in children |
| Fürnkranz A. |
- |
Oxidized phospholipids induce the human heme oxygenase-1 via CREB: a feedback mechanism in inflammatory disorders |
| Furs S. A. |
- |
Activated protein C resistance (APCR) and combined oral contraceptives: acquired APCR is more pronounced in women receiving desogestrel containing COCs than those containing levonorgestrel and is associated with low protein S levels |
| Furugohri T. |
- |
The effect of direct FXa inhibitor and direct thrombin inhibitor on TF induced DIC and venous thrombosis models in anesthetized rat – thrombin inhibitor enhance the platelet consumption in DIC model |
| Furukoji E. |
- |
Combination of increased vascular thrombogenesity and blood flow alteration promote obstructive thrombus formation in rabbit femoral artery |
| Fusch C. |
- |
Benefit and risk of heparin addition in maintaining peripheral venous catheters in neonates – a prospective, double-blind, placebo-controlled trial |
| Fusciardi J. |
- |
Changes in the platelet count (PC) after cardiopulmonary bypass (CPB) can efficiently predict the development of pathogenic heparin- dependent antibodies (Abs) |
| Fuse I. |
- |
DDAVP normalized the bleeding time in patients with congenital platelet thromboxane A2 receptor abnormality |
| Fushihara K. |
- |
EF6265: a new synthetic, potent and selective plasma CPB/TAFIa inhibitor |
| Fusinsck K. |
- |
An interactive coagulation laboratory database benefiting the entire Hemophilia Center team |
| Fuste B. |
- |
Granulocyte colony-stimulating factor exerts a pro-inflammatory effect on endothelial cells through activation of p38 MAPK |
| Fuster C. |
- |
Quantitative real-time gene expression analysis for several components of fibrinolytic and matrix metalloproteinase systems in primary breast cancer |
| Fuster V. |
- |
Intergration of vascular biology and magentic resonance imaging in the understanding of acute coronary systems |
| Futers T. S. |
- |
Complement C3 and its relationship to features of the insulin resistance syndrome and cardiovascular disease |
